How is Alpelisib regimen unique for breast cancer?

Hello,

Welcome to icliniq.com.

I read your query and can understand your concern.

Piqray (Alpelisib) is a targeted therapy medicine used to treat advanced or metastatic hormone receptor-positive (HR+), HER2-negative breast cancer with a PIK3CA mutation. This mutation, which is seen in around 40% of HR (hormone)-positive metastatic breast cancer patients, is capable of activating the PI3K-alpha isoform, increasing cancer cell proliferation and survival. Piqray efficiently targets these mutant cells by reducing PI3K enzyme activity, affecting the PI3K/AKT/mTOR signaling pathway, which is essential in cancer cell growth.

Piqray differs from other advanced breast cancer therapies in three significant ways:

1. Unlike standard chemotherapy, Piqray's targeted approach precisely targets cancer cells with the PIK3CA mutation, thereby reducing its impact on healthy cells.

2. Piqray's interference with the PI3K/AKT/mTOR pathway distinguishes it from other treatment methods, providing a viable therapeutic alternative for individuals who have established resistance to traditional therapies.

3. Piqray's oral tablet form, as opposed to intravenous or intramuscular administration of other drugs, provides patients more ease and flexibility.

However, Piqray's applicability is restricted to certain patient profiles:

1. Piqray's effectiveness depends on the presence of the PIK3CA mutation in the patient's malignancy. Piqray must be tested to determine if it is a viable therapeutic option.

2. Piqray is usually recommended for people whose cancer has progressed despite hormone treatment. If hormonal treatment continues to be beneficial, Piqray may not be required at that point.

3. Due to the potential adverse effects of Piqray, a comprehensive examination of the patient's overall health is necessary to determine if they can tolerate the therapy.

In brief, Piqray is an essential addition to the therapy spectrum for advanced breast cancer patients with the PIK3CA mutation. Its tailored strategy, distinct mode of action, and simple administration make it a viable choice for patients who have failed previous medications. However, before starting Piqray medication, it is crucial to carefully assess the patient's specific circumstances, including the presence of the PIK3CA mutation, disease progression, and overall health.

I hope this helps.

Thank you.